CSL Behring acquired Wuhan Zhong Yuan Rui De Biological Products Co. Ltd for Hemophilia treatment ma
The rising incidence and prevalence of hemophilic disorders is a prime factor fostering the growth of the Hemophilia treatment market. Key players are focussing on adopting various growth strategies such as collaborations and partnerships to develop novel therapies. This factor is again augmenting the growth of the market. For instance, in July 2019, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.
Related Bookmarks
- Bed bug treatment Nassau County
- Digital Stethoscope are gradually becoming more popular due to their amplified optimal listening, am
- Think outside the box with Ullrich Aluminium�s cube block modular system
- C�mo hacer que la ropa al por mayor de Disney para ni�os sea rentable en su negocio
- Top 18 Mobile App Development Ideas for Startups
- C�mo hacer que la ropa al por mayor de Disney para ni�os sea rentable en su negocio
- Ryfi Online
- Switch To Sustainable Makeup Remover Pads from Cotton Balls
- The Aluminium Flat Bar, more than meets the eye
- Looking For Professional Remodeling Services by Alfieri?
Recent Profiles
Keonhacai18 Club
Pia Esthetics Day Spa
Taniels Trek
Muna Strasser Dds
Kinh99net
Habib Raja
Thesaucesuite
Tarun Thapa
Jc Sotware Solution
Acute Industries